TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on May 14, 2020 (with a signature date of May 18, 2020). The filing discloses the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Firm commitment underwritten public offering of common stock.
- Shares Sold: 8,500,000 firm shares plus 1,275,000 option shares (fully exercised by underwriters on May 15, 2020), totaling 9,775,000 shares.
- Gross Proceeds: Approximately $176 million before deducting underwriting discounts, commissions, and estimated expenses.
- Underwriters: J.P. Morgan Securities LLC, Jefferies LLC, Evercore Group L.L.C., and Cantor Fitzgerald & Co. (joint book-running managers); Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC (co-managers).
- Expected Closing Date: May 19, 2020.
Material Changes and Offering Structure
The offering was upsized from a previously announced size of 6,000,000 shares to the final total of 9,775,000 shares. The transaction is being conducted pursuant to the Company's automatically effective "shelf" registration statement on Form S-3 filed on September 5, 2019.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding operational performance. It includes standard legal disclaimers noting that representations and warranties in the Underwriting Agreement were made solely for the benefit of the contracting parties and should not be relied upon by investors as characterizations of the Company's actual state of facts. The closing is subject to the satisfaction of customary conditions.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the actual closing date of the transaction (expected May 19, 2020).
- Review the final prospectus supplement filed on May 18, 2020, for the exact offering price per share.
- Assess the dilution impact of the 9,775,000 newly issued shares on existing shareholders.